Introduction
============

Despite advances in diagnosis and treatment, breast cancer remains a significant issue in women\'s health. In 2010, an estimated 207,090 women were diagnosed with breast cancer and 39,840 died of the disease^\[^[@B1]^\]^. Although death rates have dropped in recent years, breast cancer is still one of the leading causes of death for women^\[^[@B1]^\]^. Imaging is a key technology used to diagnose and assess the extent of breast cancer^\[^[@B2]^\]^. Although technological upgrades in advanced imaging are constantly improving the ability to detect breast tumors^\[^[@B3]^\]^, some of these advances have been associated with increased mastectomy rates^\[^[@B6]^\]^ and delays in beginning breast cancer treatment^\[^[@B10]^,^[@B11]^\]^. Clinical use of imaging has increased greatly in recent years^\[^[@B12]^\]^ and several analyses have found imaging to be one of the most rapidly increasing Medicare services, which has had a major impact on total health care costs^\[^[@B13]^\]^. A 2010 study found that 2-year costs for all types of cancer increased at a mean annual rate of 1.8% to 4.6% from 1999 to 2006; for diagnostic imaging specifically, however, the mean 2-year imaging costs per patient increased from 5.1% to 10.3% per year in that time^\[^[@B13]^\]^.

Unlike regulations for new drug therapies, the US Food and Drug Administration (FDA) does not require great amounts of evidence of effectiveness for new or modified imaging technologies, resulting in little motivation by device manufacturers to conduct studies documenting the long-term effects of imaging on outcomes. Comparative effectiveness research (CER) can be used to investigate whether advanced imaging technologies improve patient outcomes and decrease health care costs in diverse community settings. The Advancing Innovative Comparative Effectiveness Research (ADVICE) project engages a multi-disciplinary and cross-institutional network of stakeholders to conduct comparative effectiveness studies in western Washington State. In order to understand key gaps in evidence pertaining to the relationship between breast cancer imaging and patient outcomes that could benefit from future CER studies, we investigated the timeline of the development of several diagnostic breast imaging technologies for this article, including dates of (1) initial appearance in peer-reviewed scientific literature; (2) FDA approval; (3) Centers for Medicare and Medicaid Services (CMS) coverage; and (4) adoption into National Comprehensive Cancer Network (NCCN) guidelines. We limited the scope of this work to 5 imaging applications -- mammography, ultrasonography, magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) (now largely performed as combined PET/CT) -- that are used in the peridiagnostic period between the detection of breast cancer and the start of treatment. Many of these techniques are also used during screening, treatment monitoring, restaging, and surveillance, but these uses are not the focus of this review. We instead chose to study the peridiagnostic time period because several recent studies have questioned whether use of advanced imaging for breast cancer staging is associated with improved outcomes^\[^[@B5]^,^[@B17]^,^[@B18]^\]^. We excluded technologies that are used to detect metastases in other areas of the body, such as bone scans and MRI scans of the brain. We also report the milestones of technologies that were offshoots of the 5 main modalities, such as computer-assisted imaging, breast coils, and contrast enhancement.

Methods
=======

We performed literature searches for mammography, ultrasonography, MRI, CT, PET, and the key technological subtypes related to each in PubMed to find the first appearance in the scientific literature for use of each technology for breast tumor imaging. We restricted our search to articles published in English and excluded studies that only reported in vitro imaging. We also searched the Premarket Approval (PMA) and Premarket Notification (510(k)) databases^\[^[@B19]^,^[@B20]^\]^ on the FDA website with each technology\'s product code (the categorization scheme used to determine regulatory requirements) to find the dates of FDA approval or clearance of these devices. To find the first evidence of reimbursement for the technologies by the CMS, we searched their website (<http://www.cms.gov>) for National Coverage Determinations (NCDs) pertaining to each technology. We also investigated publicly available technology assessments from private insurers, including the Blue Cross Blue Shield Association Technology Evaluation Center^\[^[@B21]^\]^, Aetna Clinical Policy Bulletins^\[^[@B22]^\]^, and Group Health Clinical Reviews from Group Health Cooperative of Puget Sound^\[^[@B23]^\]^.

To assess the first appearance of device recommendations in national guidelines, we surveyed archives available from the National Comprehensive Cancer Network (NCCN), which represents 21 comprehensive cancer centers in the United States and is one of the most influential breast cancer diagnosis and treatment guidelines. The NCCN has been publishing guidelines for breast cancer staging, treatment, and surveillance since 1996^\[^[@B24]^\]^ and archives of guidelines from 1996 to 2011 (excluding 1998 when guidelines were not published) were available for this article^\[^[@B25]^\]^.

Results
=======

[Table 1](#T1){ref-type="table"} summarizes the dates of appearance in the peer-reviewed breast cancer literature, FDA approval, CMS reimbursement, and appearance in the NCCN guidelines of the major imaging modalities and their subsidiary technologies. Each modality is described in detail below. Table 1Milestones of major breast imaging technologies used for diagnosis and staging of breast cancerModalityAppearance in peer-reviewed breast cancer literatureFDA approval/ clearance[^a^](#TF1){ref-type="table-fn"}CMS coverage decision for breast cancerAppearance in NCCN guidelines[^b^](#TF2){ref-type="table-fn"}Mammography1960Pre-1976 MDA19781996    FFDM199620002000None    Mammography CAD198719982000NoneUltrasonography1951Pre-1976 MDA19661997MRI1973198419852001    Contrast-enhanced MRI198619882000None    MRI breast coils1985199220122002    MRS19882008NoneNoneCT1976Pre-1976 MDA19852001    Breast-specific CT1978NoneNoneNonePET1984Pre-1976 MDA2002[^c^](#TF3){ref-type="table-fn"}2003    FDG tracer199119942002[^c^](#TF3){ref-type="table-fn"}2010    PET/CT200320002009[^d^](#TF4){ref-type="table-fn"}2009[^1][^2][^3][^4][^5]

Mammography
-----------

Diagnostic mammography is typically the first imaging test used in women who have positive screening mammograms or symptoms that might be indicative of breast cancer, such as palpable breast lumps, nipple discharge or retraction, or skin changes on the breast^\[^[@B40]^\]^. Diagnostic mammography is distinguished from screening mammography in that more views are taken, usually at different magnification levels and with varying compression techniques, and often includes online review of the images and physical examination. Although we attempted to differentiate between the two types of mammography where feasible and provide information on mammography used for diagnostic purposes, we were unable to completely distinguish screening from diagnostic mammography for the milestones reported for this article ([Fig. 1](#F1){ref-type="fig"}). Figure 1Milestones in mammography. Abbreviations: MM, mammography; HIP, Health Insurance Plan of Greater New York; FDA, US Food and Drug Administration; MDA, Medical Device Amendments of 1976; CMS, Centers for Medicare and Medicaid Services; CAD, computer-aided detection; NCCN, National Comprehensive Cancer Network; FFDM, full field digital mammography; DMIST, Digital Mammographic Imaging Screening Trial.

Use of x-rays to examine breast tissue was reported as early as 1913 by A. Salomon^\[^[@B41]^\]^, but the first peer-reviewed report of use of this technology to diagnose breast cancer was from R.L. Egan in 1960^\[^[@B42]^\]^. A randomized control trial conducted by the Health Insurance Plan (HIP) of Greater New York, published in 1973, showed a 33% reduction in breast cancer mortality for women screened with mammography and helped this modality achieve widespread clinical acceptance^\[^[@B43]^\]^. Full field digital mammography (FFDM) utilizes digital detectors rather than x-ray film to improve some of the inherent weaknesses of film-based radiology, such as lack of contrast range. The first reference in the scientific literature to the design of FFDM was by M.B. Williams in 1996^\[^[@B44]^\]^ and a randomized controlled trial showing that the overall accuracy of FFDM and film mammography were the same, with improvements with FFDM in some subgroups, was published in 2005 by the ACRIN group, which conducted the Digital Mammographic Imaging Screening Trial (DMIST)^\[^[@B45]^\]^. Computer-aided detection (CAD; sometimes referred to as computer aided diagnosis) uses image processing and computer vision techniques to augment a human reader\'s ability to detect breast lesions. The first paper to discuss this application for breast tumors was published by Chan in 1987^\[^[@B46]^\]^ and the first commercial CAD mammography systems appeared in 1998^\[^[@B47]^\]^.

Because mammography was used clinically prior to the Medical Device Amendments (MDA) of 1976, analog (film screen) mammography did not receive FDA premarket approval or 510(k) clearance. CAD interpretation of mammography received FDA approval in 1998^\[^[@B48]^\]^. In January 2000, the FDA approved FFDM for screening and diagnosis of breast cancer for the same clinical indications as traditional film-based mammography^\[^[@B19]^\]^.

CMS has covered diagnostic mammography since May 1978 for patients with distinct signs and symptoms, a history of breast cancer, or are asymptomatic but for whom physicians deem mammography appropriate^\[^[@B49]^\]^. Digital mammography and mammography CAD for both screening and diagnostic mammography have been reimbursed by CMS since 2001 as a result of the Benefits Improvement and Protection Act (BIPA) of 2000^\[^[@B50]^\]^. Most private insurers now reimburse FFDM, but the evaluation of mammography CAD is mixed. For example, a recent report from the Blue Cross Blue Shield Association stated that the evidence for mammography CAD for diagnostic purposes was insufficient^\[^[@B51]^\]^; an Aetna Clinical Policy Bulletin stated CAD was "a medically necessary adjunct to mammography"^\[^[@B52]^\]^.

Guidelines published by the NCCN have recommended that diagnostic mammography be used for local breast staging for breast cancer (determining the extent of disease in the breast) since 1996^\[^[@B25]^\]^. FFDM and mammography CAD have never received specific mention in NCCN guidelines.

Ultrasonography
---------------

The earliest reports of the use of ultrasound technology to examine breast tissue were reported in 1951, when it was used to visualize benign and malignant tumors and to determine the extent of metastases ([Fig. 2](#F2){ref-type="fig"})^\[^[@B53]^,^[@B54]^\]^. In the late 1970s, concern about the level of radiation from mammography led to an interest in utilization of ultrasonography to screen for breast cancer. However, ultrasonography generally has a number of limitations compared with mammography, including lower detection of microcalcifications, inability to differentiate benign from malignant solid lesions, and poor imaging of masses smaller than 1 cm in diameter, and was determined to be impractical as a substitute for screening mammography^\[^[@B55]^\]^. Figure 2Milestones in ultrasound imaging of the breast. Abbreviations: CMS, Centers for Medicare and Medicaid Services; FDA, US Food and Drug Administration; MDA, Medical Device Amendments of 1976.

Breast ultrasonography is currently used to supplement mammograms for screening^\[^[@B56]^\]^, to distinguish benign cysts from solid masses^\[^[@B57]^\]^, for image-guided interventions such as large-core breast and fine-needle aspiration biopsies^\[^[@B55]^,^[@B58]^\]^, and for local breast staging. It is increasingly used for locoregional staging as well, for determining the status of locoregional lymph nodes^\[^[@B59]^\]^. Ultrasonography is also the primary method of imaging palpable breast masses in women under 30 years old, since the density of the breast tissue in younger women rules out mammography^\[^[@B58]^\]^. Ultrasonography is recommended for surveillance in women who have had mastectomies^\[^[@B60]^\]^ and breast conservation therapy^\[^[@B63]^,^[@B64]^\]^.

Conventional ultrasound devices were on the market prior to the MDA of 1976 and therefore most were excluded from original FDA approval. (The exception is the HDI 3000 US System, which was approved under the PMA process in 1996 as an adjunct to mammography and physical breast examination^\[^[@B65]^\]^.) CMS has covered breast ultrasonography since 1966^\[^[@B66]^\]^.

Since 1997, the NCCN has indicated that ultrasonography can be used as part of the work-up for women with clinical indications of all stages of breast cancer^\[^[@B26]^\]^.

MRI
---

Use of MRI for examining malignant breast tissue was first reported by R. Damadian and colleagues in 1973^\[^[@B67]^\]^, but the usefulness of MRI in relation to breast cancer was not appreciated until contrast agents, which enhanced the appearance of tumors compared with normal tissue, were introduced in 1986 ([Fig. 3](#F3){ref-type="fig"})^\[^[@B68]^\]^. The quality of breast MRI was also enhanced by the introduction of breast imaging coils, first reported in 1985^\[^[@B69]^\]^. Magnetic resonance spectroscopy (MRS) uses modified MRI hardware and software to characterize the chemical composition of breast tumors since some proton MRS studies showed that breast cancers exhibit increased levels of choline compared with normal tissue, but remains largely investigational^\[^[@B70]^\]^. This technology was first reported in the peer-reviewed literature for use with breast tumors in 1988^\[^[@B71]^\]^, although in vitro studies were published prior to this^\[^[@B67]^\]^. Figure 3Milestones in MRI of the breast. Abbreviations: MRI, magnetic resonance imaging; FDA, US Food and Drug Administration; CMS, Centers for Medicare and Medicaid Services; MRS, magnetic resonance spectroscopy; Gd, gadolinium; NCCN, National Comprehensive Cancer Network.

The FDA approved MRI scanners, the first imaging devices to be approved through the PMA process as class III devices, in 1984^\[^[@B19]^,^[@B65]^\]^. In 1991, MRI was reclassified for use as a supplement to mammography to diagnose breast cancer^\[^[@B65]^\]^. Gadolinium-based contrast agents (GBCAs), currently the only FDA-approved contrast agents for evaluation of the breast, received FDA clearance in 1988^\[^[@B72]^\]^. Breast coils for MRI were cleared through the 510(k) process in 1992^\[^[@B20]^\]^. MRS received FDA 510(k) clearance in 2008^\[^[@B73]^\]^.

CMS began reimbursing for breast MRI, as long as the MRI unit had received FDA premarket approval, in November 1985^\[^[@B74]^\]^. Although no NCD was given specifically for contrast MRI, legislation in 2000 directed the Health Care Financing Administration to create separate billing codes for contrast agents and imaging procedures, which allowed CMS to pay for these separately. Currently, no additional reimbursement is made for imaging with dedicated breast coils, but as a result of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA), facilities will be required to use breast coils in order to receive Medicare reimbursements for breast MRIs beginning in 2012. Although many private insurers require preauthorization for diagnostic breast MRI, most reimburse for it in at least some cases^\[^[@B75]^\]^. Currently MRS is not reimbursed by CMS^\[^[@B76]^\]^ and private insurers view the test as experimental^\[^[@B77]^\]^.

NCCN guidelines stated that body MRI, specifically abdominal MRI, might be used for symptomatic areas for systemic staging of women with metastatic or recurrent breast cancer beginning in 1996^\[^[@B26]^\]^. However, breast MRI, which is distinct from MRI for body imaging, was not addressed until 2001, when it was mentioned as optional for women with clinical stages I, IIA, and IIB breast cancers, largely for local breast staging^\[^[@B29]^\]^. In 2002, the guidelines specified that a dedicated breast coil should be used, although the MRI was still listed as optional and only in patients with equivocal results from other tests who were considering breast conserving therapy^\[^[@B30]^\]^. Beginning in 2004, the option of breast MRI was extended to women with clinically identified stage III cancer^\[^[@B32]^\]^. In 2005, language was added to the guidelines to emphasize that whether to perform breast conservation therapy or mastectomy should not be decided solely on the basis of results from the MRI^\[^[@B33]^\]^. Further caveats were added in 2007, such as that MRI should not replace diagnostic mammography or ultrasonography and that the MRI should be performed and read by an expert breast imaging team^\[^[@B35]^\]^. Beginning in 2008, guidelines for inflammatory breast cancer were included and these listed breast MRI as optional^\[^[@B36]^\]^. From 2009 to 2011, the guidelines also included the stipulation that no data had indicated that use of MRI to choose local therapy improved outcomes (e.g. recurrence or survival) and false-positive findings from MRI were common^\[^[@B37]^\]^. MRS has not been mentioned in the NCCN guidelines.

CT
--

The algorithms that enable reconstruction of cross-sectional imaging in CT were introduced by D.E. Kuhl and R.Q. Edwards in 1962 ([Fig. 4](#F4){ref-type="fig"})^\[^[@B78]^\]^. The first peer-reviewed documentation of the use of CT technology in the diagnosis of breast lesions was reported by D.F. Reese et al. in 1976^\[^[@B79]^\]^ and the first use of a dedicated breast CT scanner was reported in 1978 by C.H. Chang and colleagues^\[^[@B80]^\]^. Although CT initially sparked interest for detecting malignancies, concerns about its specificity, radiation dose, and exposure to iodinated contrast agents that can cause allergic reactions prevented its adoption into regular use for diagnosis and staging of breast cancer patients^\[^[@B81]^\]^. Figure 4Milestones in computed tomography (CT) imaging of the breast. Abbreviations: CT, computed tomography; FDA, US Food and Drug Administration; MDA, Medical Device Amendments of 1976; CMS, Centers for Medicare and Medicaid Services; NCCN, National Comprehensive Cancer Network.

Commercial CT systems existed before the 1976 MDA and therefore CT has no date of initial FDA approval. To date, a breast-specific CT device has not been cleared by the FDA, although there has been some recent renewed enthusiasm for this device^\[^[@B84]^\]^. CT has been covered by CMS since November 1985 for a variety of indications, but the coverage decision did not specify whether breast cancer staging was among them^\[^[@B85]^\]^.

NCCN guidelines for CT relate to its use for systemic staging of breast cancer. Although NCCN guidelines recommended abdominal CT for stage III breast cancers beginning in 1996, chest CT was not mentioned until 2001, when the guidelines stated that consideration could be given to using chest CT in women with stage II cancer with at least 4 positive nodes^\[^[@B25]^\]^. In 2002, the guidelines also stated that chest CT could be considered for women with stage IV or recurrent breast cancers^\[^[@B30]^\]^. Beginning in 2003, the guidelines recommended use of chest CT for stage III breast cancer and also indicated that CT should be used for treatment planning when radiation therapy was to be delivered to the mammary lymph node field^\[^[@B31]^\]^. From 2006 to 2011, chest CT was still a consideration for women with stages I or II cancer with at least 4 positive nodes and was recommended for treatment planning, but, for work-up of clinical stages III, IV, and recurrent cancers, the guidelines stated that chest imaging should be done and did not specifically mention CT^\[^[@B34]^\]^. Beginning in 2008, guidelines for inflammatory breast cancer were included and these recommended chest CT to evaluate for the presence of distant metastases^\[^[@B36]^\]^.

Fluorodeoxyglucose(FDG)-PET and FDG-PET/CT
==========================================

Because tumors have increased glucose utilization rates compared with non-cancerous tissue, FDG-PET has potential to be an effective imaging test in oncology^\[^[@B86]^\]^. However, PET scans are not widely used for diagnosis and staging breast cancer because they are expensive and can have poor sensitivity for detection of small tumors and ductal carcinoma in situ (DCIS) compared with other imaging techniques^\[^[@B87]^\]^.

As with CT technology, prototype PET systems appeared shortly after D.E. Kuhl and R.Q. Edwards introduced reconstruction algorithms for emission CT in 1962 ([Fig. 5](#F5){ref-type="fig"})^\[^[@B90]^\]^. The first commercially available PET system, the ECAT II, was developed by E&G Ortec in 1976^\[^[@B90]^\]^. Studies evaluating PET in breast cancer patients first appeared in 1984^\[^[@B91]^\]^. and the first study to evaluate the use of FDG as a tracer for use of PET on breast cancer patients was reported in 1991^\[^[@B94]^\]^. D.W. Townsend and colleagues developed the first combined PET/CT prototype in 1998^\[^[@B95]^\]^. Its first use in breast cancer patients was reported in 2003^\[^[@B96]^\]^. By 2006, all scanners purchased in the United States were combined PET/CT^\[^[@B88]^\]^. Since the ECAT II system was introduced before implementation of the 1976 MDA, it was marketed without FDA premarket approval or 510(k) clearance. PET may be used with a number of different radiotracers, but the only FDA-approved tracer for breast imaging is FDG, which received initial FDA approval in 1994 for the identification of regions associated with epileptic seizures^\[^[@B97]^\]^. In 1999, the FDA Center for Drug Evaluation and Research (rather than the Center for Devices and Radiological Health, which approved PET scanners) approved FDG for use as a radiopharmaceutical^\[^[@B97]^\]^ and in 2000 it was approved for oncologic purposes^\[^[@B98]^\]^. Also in 2000, the first PET/CT device received 510(k) clearance^\[^[@B99]^\]^. Figure 5Milestones in PET imaging of the breast. Abbreviations: PET, positron emission tomography; FDA, US Food and Drug Administration; MDA, Medical Device Amendments of 1976; FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography; CMS, Centers for Medicare and Medicaid Services; NCCN, National Comprehensive Cancer Network.

PET scans were reimbursed by CMS for breast cancer patients in 2002 as an adjunct to other imaging modalities for (1) staging breast cancer patients with distant metastases, (2) restaging patients with locoregional recurrence or metastases, and (3) monitoring tumor response to treatment for women with locally advanced and metastatic breast cancer if a change in therapy was considered^\[^[@B100]^\]^. Use of PET for diagnosis of breast cancer and staging of axillary lymph nodes for breast cancer patients was not covered by CMS^\[^[@B100]^\]^. Although no changes were made to the reimbursement decisions on the use of PET for breast cancer, CMS issued another NCD in 2009 that made changes to PET with regard to other types of cancer and this indicated that PET/CT scanners were covered in the same manner as PET-only machines^\[^[@B101]^\]^. Private insurers use similar criteria as CMS for decisions about reimbursement for PET scans in breast cancer patients^\[^[@B102]^\]^.

Use of PET scans in the NCCN guidelines relates to systemic and locoregional staging. Use of PET scans was first incorporated into NCCN guidelines in 2003, when they were described as an optional imaging procedure for stage IV metastatic or recurring breast cancer; however, the guidelines recommended that PET scans not replace more established imaging methods^\[^[@B31]^\]^. This remained consistent until 2007^\[^[@B32]^\]^ but in 2008, PET or PET/CT scans were not mentioned in the guidelines^\[^[@B36]^\]^. The 2009--2011 NCCN guidelines specified that PET (and, for the first time, PET/CT was specifically mentioned) were *not* indicated for (1) detecting primary breast cancer, (2) staging of the primary tumor, axilla, or metastatic disease in patients with early-stage disease, or (3) post-treatment disease surveillance^\[^[@B37]^\]^. However, the guidelines indicated that PET/CT scans may be considered as an adjunct to other imaging modalities for initial evaluation of recurrent or metastatic disease, locally advanced, or inflammatory breast cancer when the results of other imaging tests were unclear, but even then, the guidelines stated that biopsies would probably be more informative than PET or PET/CT scans^\[^[@B37]^\]^. FDG was specified in the guidelines beginning in 2010^\[^[@B38]^\]^.

Discussion
==========

In this article, we tracked the chronology of development of imaging modalities that are commonly used for diagnosis and staging of breast cancer. Although peer-reviewed papers documenting the ability of these technologies to image breast tumors appeared as early as the 1950s, FDA approval or clearance and CMS reimbursement often took place years later. We found that 4 of these technologies (mammography, ultrasonography, CT, and PET) were widely used before 1976 and never received initial FDA approval. Mammography and ultrasonography have been reimbursed by CMS for more than 30 years and are commonly used for diagnosis and staging of breast cancer^\[^[@B39]^\]^. Although CT is covered by CMS for some indications, breast cancer is not specified as one and its diagnostic use for breast cancer has never been strongly advocated in NCCN guidelines. MRI received FDA approval and CMS reimbursement coverage in the mid-1980s, but NCCN guidelines have been very cautious about its use for diagnosis and staging. For women with non-metastatic breast cancer, PET and PET/CT have not been covered by CMS or recommended by NCCN guidelines but, nonetheless, anecdotal evidence indicates their use is not uncommon.

The factors driving acceptance and clinical use of new imaging technologies are complex. FDA regulatory approval is crucial, but without CMS reimbursement, technologies are unlikely to be widely used. For example, MRI was approved by the FDA in 1984, reimbursed by CMS 1 year later, and utilization rates began soaring immediately^\[^[@B103]^\]^. In contrast, PET was commercially available from 1976 but its use did not extend beyond the research setting until CMS began reimbursing for numerous cancer indications in 2001^\[^[@B104]^\]^. However, CMS reimbursement does not automatically translate to increased use in the clinic; for example, CT has been FDA-approved since 1976 and reimbursed by CMS since 1985, but since early studies did not show convincing evidence of benefit compared with other techniques, few clinicians have used CT for detection and locoregional assessment of breast lesions^\[^[@B13]^\]^.

The FDA requirements for approval of imaging technologies are not very stringent, resulting in few studies documenting long-term effects on outcomes such as disease recurrence or survival that would be required for novel drug therapies. The evidence of effectiveness of diagnostic breast imaging technologies varies. Diagnostic mammography, for example, has generally been used without controversy in patients with suspicious breast lesions because several studies have shown it has fairly high sensitivity and specificity, ranging from 78% to 93% and from 87% to 98%, respectively^\[^[@B40]^,^[@B105]^\]^, and because its use as a screening tool has been shown to reduce breast cancer mortality^\[^[@B110]^\]^. Similarly, use of ultrasonography for diagnostic breast imaging is generally not controversial because it is not invasive, does not entail exposure to radiation, and evidence indicates that its use is advantageous compared with other imaging modalities in some situations such as differentiating benign cysts from solid masses^\[^[@B57]^\]^ or examining dense breast tissue in younger women^\[^[@B58]^\]^. On the other hand, evidence for long-term benefits stemming from use of MRI, CT, and PET or PET/CT in the peridiagnostic period is lacking (although some evidence has shown that use of MRI for screening high-risk women leads to reduced diagnoses of advanced-stage breast cancer compared with women screened conventionally)^\[^[@B111]^\]^. While diagnostic MRI has great potential to detect otherwise occult cancers, whether these findings actually lead to reductions in re-excision, recurrence, and mortality rates has not been shown^\[^[@B17]^,^[@B18]^,^[@B112]^,^[@B113]^\]^. Furthermore, the high rate of false-positive MRI scans may lead to harmful consequences such as greater rates of (sometimes unnecessary) mastectomies^\[^[@B6]^\]^ and delays in beginning treatment^\[^[@B10]^,^[@B11]^\]^. Similarly, a review published by the Agency for Healthcare Research and Quality (AHRQ) in 2006 concluded that the negative predictive value of PET, at 64.8%, was too low to indicate routine use for ruling out breast cancer after detection of abnormalities^\[^[@B114]^\]^. Similarly, the 2011 NCCN guidelines cited evidence that PET scanning has a high false-negative rate for detection of lesions less than 1 cm, low sensitivity for detection of metastases, and a high rate of false-positive scans, and recommended that PET or PET/CT not be used for staging breast cancer in most cases^\[^[@B39]^\]^. CT has not been widely used for breast imaging, likely because small studies indicated that it was not as sensitive and specific compared with other modalities^\[^[@B115]^\]^ and could entail substantially greater radiation exposure^\[^[@B83]^\]^.

Although regulatory and reimbursement structures in the United States are generally distinct from other countries, advanced diagnostic breast imaging technologies are commonly used internationally, as shown by recent publications from international research centers investigating the usefulness of diagnostic breast advanced imaging^\[^[@B18]^,^[@B119]^\]^. One of these, a recent randomized controlled trial conducted at 45 clinical centers in the United Kingdom, showed no difference in re-excision rates in women randomized to receive MRI versus women assigned to receive usual care (clinical, radiologic (mammogram and ultrasound scan), and pathologic assessment)^\[^[@B18]^\]^. The other, a randomized controlled trial conducted in The Netherlands, found an increase in re-excision rates in women who were randomized to receive pre-operative MRI compared with women who received routine medical care^\[^[@B119]^\]^. Although utilization rates of advanced breast imaging technologies in non-US health systems are likely driven by different factors than those in the United States, research on the most appropriate use of these modalities is lacking and investigations on these evidence gaps would be useful worldwide.

Although randomized controlled trials are considered the gold standard in identifying best medical practices, these are impractical for determining the best uses of advanced imaging, including imaging for staging and work-up of breast cancer, for several reasons. Imaging technologies are constantly changing so by the time clinical trials are completed, technologies are often obsolete and the results are no longer applicable to clinical care^\[^[@B120]^\]^. Also, although no long-term studies have shown improvements in breast cancer recurrence or survival rates as a result of receipt of advanced imaging, many clinicians and patients believe that the added information derived from imaging must lead to better care^\[^[@B121]^\]^, so withholding imaging from breast cancer patients could be viewed as unethical. The situation is also complicated by the array of tests and treatments available to breast cancer patients and differentiating the role on outcomes that imaging has compared with other variables is difficult^\[^[@B122]^\]^.

Because many of these imaging technologies are widely used with little evidence that they affect long-term outcomes in breast cancer patients, CER is as an ideal method to investigate whether advanced imaging technologies improve patient outcomes and/or decrease costs in real-world settings. Unlike randomized controlled trials that restrict variation as much as possible, CER studies examine as many alternative diagnostic tests and therapies as the data allow and often have much larger numbers of subjects to study because strict inclusion and exclusion criteria are not factors. The wide variety of patients that can be studied allows CER results to be generalizable to entire communities rather than specific patient populations. Two key imaging societies for breast imaging, the American College of Radiology Imaging Network (ACRIN) and the Society for Nuclear Medicine (SNM), have embraced CER^\[^[@B123]^,^[@B124]^\]^. Although CER was not used to evaluate these breast imaging technologies prior to FDA approval, recent publications have reported use of this research to examine diagnostic breast imaging^\[^[@B18]^,^[@B125]^\]^ and CER is a vital component in determining international guidelines^\[^[@B126]^\]^. An integral part of CER is involvement of stakeholders in the identification and prioritization of research topics to ensure that the research studies are relevant^\[^[@B127]^\]^. For CER pertaining to diagnostic breast imaging, the key stakeholders from the community would likely be payers, breast oncologists and other health care providers, and breast cancer patients or survivors^\[^[@B127]^\]^.

Historically, breast imaging technologies have followed varying paths from appearing in the peer-reviewed literature to being recommended for use in clinical guidelines. Some, such as ultrasonography and mammography, were discovered decades before their use was appreciated. Others, such as MRI, were reported in the literature, approved by the FDA, reimbursed by CMS, and mentioned as optional imaging modalities in clinical guidelines in a fairly short period. This article demonstrates that some of these breast imaging technologies reached widespread use with very little data that they improved breast cancer outcomes, such as reducing recurrence rates or increasing survival time, or decreased costs. By tracing the dates of discovery, FDA clearance or approval, reimbursement, and adoption into clinical guidelines of each diagnostic imaging technology, we show that these milestones were often achieved without evidence of positive effects on long-term outcomes in breast cancer patients. The fact that these historic milestones occurred with little evidence that they improved long-term outcomes demonstrates that CER is much needed for diagnostic breast cancer imaging research. In addition, CER is an important tool to study the many emerging diagnostic imaging technologies that have not yet come into widespread use so that modalities that improve long-term outcomes can be favored over those that do not. In order to ensure that only the most effective and cost-efficient imaging technologies reach or remain in clinical practice, CER will play a critical role in evaluation of future diagnostic technologies.

This paper is available online at <http://www.cancerimaging.org>. In the event of a change in the URL address, please use the DOI provided to locate the paper.
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[^1]: Abbreviations: FDA, US Food and Drug Administration; CMS, Centers for Medicare and Medicaid Services; NCCN, National Comprehensive Cancer Network; MDA, Medical Device Amendments of 1976; FFDM, full field digital mammography; CAD, computer-aided detection; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; CT, computed tomography; PET, positron emission tomography; FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography.

[^2]: ^a^FDA approval/clearance not necessarily for breast cancer indications.

[^3]: ^b^Guidelines first published by NCCN in 1996.

[^4]: ^c^Covered only for metastatic breast cancer.

[^5]: ^d^PET/CT was not specifically mentioned in a coverage determination prior to 2009, but was probably covered under the same conditions as PET.
